Award Data

Multiple myeloma is incurable hematologic malignancy with an expected median survival of years The proteasome inhibitors bortezomib carfilzomib and the recently approved ixazomib are a mainstay of current myeloma treatment Despite an initial response rate approaching to proteasome inhibitor containing combinations all patients relapse and eventually become resistant to any treatments ...

ABSTRACT Modulation Therapeutics is developing a first in class cyclic peptide coined MTI for the treatment of multiple myeloma The company currently has a license for the parent molecule which has been awarded a patent covering the intellectual property for both composition of matter and use in cancer in the US and Europe Modulation Therapeutics is now poised to further advance this class ...

Summary Approximatelymillion women in the United States are at high risk for developing breast cancerbased on inheritance of a germline mutation in a gene in the double strand breakDSBrepair and cyclin checkpoint pathwaysMany are unaware of their genetic predispositionsbecause their family history is uninformative or unknownGenetic testing is important for identifying mutations in these genesbut i ...

Checkpoint inhibitors towards targets such as PDand PD Lare being developed to activate quiescent T cells embedded in tumors and enable them to recruit the rest of the immune system to fight a cancer massHow these new cures reactivate the relatively few Tumor Infiltrating LymphocytesTILsenabling the release of a complex message of cytokines to recruit the immune systemthus impacting treatment effi ...

With this PhasesubmissionIsoPlexis proposes to deliver a single cell proteomic solution for ultra sensitive detection of unique correlative biomarkers in pre clinical mouse modelsin an automated system that can be used to accelerate the discovery of potential immune therapeuticsThe recent revolution in new basic science discovery is failing to translate into improved patient treatmentThe reduction ...

Project Summary Systemic sclerosis SSc is a systemic autoimmune disease that results in widespread fibrosis of the skin and internal organs vascular dropout and autoantibody formation SSc has the highest case fatality rate of any systemic autoimmune disease and there remain for FDA approved therapies Analysis of gene expression data on samples collected from SSc patients strongly indicates th ...

Abstract Project Summary Scleroderma Systemic Sclerosis SSc is an autoimmune disease of unknown etiology that is characterized by vascular dysfunction fibrosis and inflammation One in three patients dies within years of diagnosis giving SSc the highest case fatality rate of any systemic autoimmune disease A lack of biologically relevant human SSc disease models has created a critical ...

Abstract Primary central nervous system lymphoma PCNSL is an aggressive brain tumor with a dire unmet therapeutic need It has an overall incidence of per person years and is regarded as an orphan disease with potential for fast track approval Our group made a discovery via gene expression analysis that osteopontin OPN is the most upregulated gene in PCNSL compared to its non CNS ...

Project Summary Rodent borne viral outbreaks are increasing in both frequency and impactAs weather patterns evolverodent populations are affected and may multiply in areas where increased contact with humans results in infectionHantavirusesincluding AndesANDVand Sin NombreSNVare transmitted through the excreta of infected rodents andwhen aerosolizedinfect humansIn the Americashantavirus infection ...

ImmuNext has identified and developed a putative lead anti VISTA monoclonal antibodymAbthat we aim to bring to the clinic for the treatment of human autoimmune diseaseVISTA is a member of the highly successful negative checkpoint regulatorNCRfamily of drug targetswhose members have demonstrated proven efficacy in inducing long term remissions in human cancersWe contend that antibodies that suppres ...